Address: Memorial Sloan-Kettering Cancer Center 1275 York Ave New York, New York 10021
Dr. David H. Ilson is a medical oncologist with experience in treating patients with upper gastrointestinal cancers, specifically those with esophageal cancer. His clinical expertise covers several areas including: colorectal, esophageal, pancreatic, gastric and other gastrointestinal cancers, as well as unknown primary tumors, namely, mesothelioma.
Dr. Ilson’s research focuses on studying new agents to treat advanced disease and evaluating novel agents in combined-modality therapy as a means of treating locally advanced diseases. He is currently an Associate Physician at the Memorial Sloan-Kettering Cancer Center in New York, and an Associate Professor at Weill Medical College of Cornell University.
Education and Training
Dr. Ilson completed his undergraduate work at the University of Connecticut, and received his medical doctorate, doctorate of philosophy, and master’s degree as part of a combined degree program at New York University. His doctorate of philosophy and master’s degree are in basic science. He completed a fellowship in medical oncology and hematology at Memorial Sloan-Kettering Cancer Center and fulfilled his internship and residency in internal medicine at Bellevue Hospital, which is part of New York University’s Medical Center.
Dr. Ilson is Board Certified in Internal Medicine and Medical Oncology.
Research and Publications
Currently, Dr. Ilson is a member of the GI committees of the national clinical research groups: Cancer and Leukemia Group B (CALGB) and the Radiation Therapy Oncology Group (RTOG). He is also a member of the Upper GI Cancer Guidelines Committee of National Comprehensive Cancer Network (NCCN) and chairman of the Intergroup Esophageal and Gastric Cancer Task Force Committee.
Among numerous publications in peer-reviewed journals such as the Journal of Thoracic Oncology, Dr. Ilson participated in the Seminar of the Open Medical Institute. This seminar was held at Schloss Arenberg in Salzburg, Austria and involved faculty from Memorial Sloan-Kettering Cancer Center, as well as 33 physcians from 19 countries and regions across Eastern Europe and Central Asia. Dr. Ilson was one of the lecturers during this symposium and spoke on the following topics:
A paper he co-authored appearing in the Journal of Clinical Oncology, researched docetaxel,cisplatin, and fluorouracil. Cisplatin is a chemotherapy drug that was approved by the Federal Drug Administration for the treatment of mesothelioma in 1978.